Request More Information

SpaceOAR® Hydrogel News

RECENT ARTICLES

Augmenix, Inc. Announces SpaceOAR® Hydrogel is Now Available to Millions More Americans

Augmenix, Inc. is pleased to announce that the company’s leading product, SpaceOAR hydrogel, is now available to millions of American men covered under Medicare, Medicaid, and Aetna, Inc.

Read More

Beaumont Hospital Using SpaceOAR® Hydrogel To Reduce Side Effects of Prostate Cancer Treatment

The hydrogel is placed by Dr. Daniel Krauss, MD., a radiation oncologist with a primary focus on prostate and bladder cancers. He places the gel under local or general anesthesia in an outpatient setting. He is a leading expert in prostate cancer treatment with brachytherapy, a high-dose, internal radiation treatment.

Read More

UsToo and Dr. Daniel Fried Present Live Webcast and Q and A on Prostate Cancer Radiation Therapy

The event featured a presentation from renowned radiation oncologist Daniel B. Fried, MD, MPH, PhD, who practices at the Gibbs Cancer Center and Research Institute in Greenville, S.C discussing radiation therapy as an option for prostate cancer treatment.

Read More

Augmenix, Inc. Announces Aetna’s Positive Coverage Decision for the SpaceOAR® Hydrogel

  |    |  
Read More

The Relaunch of SpaceOAR Hydrogel Clinical Publications!

Now it’s easier than ever to find the peer-reviewed papers, abstracts and posters that evaluate the efficacy of SpaceOAR hydrogel.

Read More

Augmenix® Announces Medicare Reimbursement Rates for 2018

Augmenix® Announces Medicare Reimbursement Rates for the new CPT Code 55874, which will be used to bill SpaceOAR® Hydrogel, Effective January 2018

Read More

No Results were found

Please try to expand your search or search within our categories
See All Results >
View more articles